ArticleJournal of cardiothoracic surgery2026
SRPRA affects hyperoxia-induced bronchopulmonary dysplasia by modulating endoplasmic reticulum stress through the CHOP pathway.
Article in Journal of cardiothoracic surgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundBronchopulmonary dysplasia (BPD) is a prevalent chronic lung disease among preterm infants, largely attributed to hyperoxia-induced injury to alveolar epithelial cells. Excessive endoplasmic reticulum (ER) stress plays a vital role in BPD progression. SRPRA, a subunit of the ER-localized SRP receptor, is upregulated in BPD, while its function and link with ER stress remain largely unclear. This study aimed to explore the role of SRPRA in hyperoxia-induced BPD and its underlying mechanism.
methodsA hyperoxia-exposed alveolar type II epithelial cell (AECII) model was established to mimic BPD in vitro. Cell viability, cell proliferation and apoptosis were detected by CCK-8, EdU assay and flow cytometry, respectively. The secretion of inflammatory factors was evaluated via ELISA assay. ROS levels were detected by DCFH-DA fluorescence staining. Commercial kits were used to detect MDA and SOD levels. The SRPRA mRNA level and protein expression was measured using qRT-PCR and Western blot. Expression levels of apoptosis-related proteins (Bax, Bcl2), inflammation-related proteins (iNOS, Cox2) and CHOP pathway-related proteins were assessed by western blotting.
resultsSRPRA was markedly upregulated in hyperoxia-induced alveolar epithelial cells. Hyperoxia stimulation decreased viability and proliferation, and enhanced apoptosis in AECIIs, accompanied by elevated inflammatory responses and oxidative stress. SRPRA knockdown alleviated hyperoxia-induced cell damage, inflammation and oxidative stress, and downregulated the expression of CHOP (a key mediator of ER stress). The protective effects mediated by SRPRA silencing were largely reversed by thapsigargin.
conclusionSRPRA knockdown alleviates hyperoxia-induced AECII injury by attenuating CHOP-mediated ER stress. Our findings reveal the pathogenic role of SRPRA in BPD, and suggest SRPRA as a potential therapeutic target for this disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.